No products in the cart.

Anti-TNAP3 antibody

SKU Product Brand Unit Availability Price Quantity  
AB-07-2188
Anti-TNAP3 antibody
Erpan Tech In stock

Specifications        

Product Cat#: AB-07-2188
Product type: Primary antibody
Antigen: TNAP3
Immunogen: The antiserum was produced against synthesized peptide derived from internal of human TNAP3.
Species immunized: Rabbit
Isotype: IgG
Applications: Western Blot (1:500-1:2500); Immunofluorescence (1:100-1:500); ELISA (1:15000)
Reactivity: Human, Mouse
Clonality (clone number): Polyclonal
Form: Liquid
Buffer: Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Concentration: 1 mg/ml
Purity: Antigen affinity chromatography
Storage: Aliquot and freeze at -20°C. Avoid multiple freeze/thaw cycles.
Alternative names: A20, DNA binding protein A20, EC 3.-.-.-, TNAP3, TNFA1P2, Tumor necrosis factor, Alpha-induced protein3, Zinc finger protein A20
Show More

Target information

Ubiquitin-editing enzyme that contains both ubiquitin ligase and deubiquitinase activities. Involved in immune and inflammatory responses signaled by cytokines, such as TNF-alpha and IL-1 beta, or pathogens via Toll-like receptors (TLRs) through terminating NF-kappa-B activity. Essential component of a ubiquitin-editing protein complex, comprising also RNF11, ITCH and TAX1BP1, that ensures the transient nature of inflammatory signaling pathways. In cooperation with TAX1BP1 promotes disassembly of E2-E3 ubiquitin protein ligase complexes in IL-1R and TNFR-1 pathways; affected are at least E3 ligases TRAF6, TRAF2 and BIRC2, and E2 ubiquitin-conjugating enzymes UBE2N and UBE2D3. In cooperation with TAX1BP1 promotes ubiquitination of UBE2N and proteasomal degradation of UBE2N and UBE2D3. Upon TNF stimulation, deubiquitinates ‘Lys-63’-polyubiquitin chains on RIPK1 and catalyzes the formation of ‘Lys-48’-polyubiquitin chains. This leads to RIPK1 proteasomal degradation and consequently termination of the TNF- or LPS-mediated activation of NF-kappa-B. Deubiquitinates TRAF6 probably acting on ‘Lys-63’-linked polyubiquitin. Upon T-cell receptor (TCR)-mediated T-cell activation, deubiquitinates ‘Lys-63’-polyubiquitin chains on MALT1 thereby mediating disassociation of the CBM (CARD11:BCL10:MALT1) and IKK complexes and preventing sustained IKK activation. Deubiquitinates NEMO/IKBKG; the function is facilitated by TNIP1 and leads to inhibition of NF-kappa-B activation. Upon stimulation by bacterial peptidoglycans, probably deubiquitinates RIPK2. Can also inhibit I-kappa-B-kinase (IKK) through a non-catalytic mechanism which involves polyubiquitin; polyubiquitin promotes association with IKBKG and prevents IKK MAP3K7-mediated phosphorylation. Targets TRAF2 for lysosomal degradation. In vitro able to deubiquitinate ‘Lys-11’-, ‘Lys-48’- and ‘Lys-63’ polyubiquitin chains. Inhibitor of programmed cell death. Has a role in the function of the lymphoid system. Required for LPS-induced production of proinflammatory cytokines and IFN beta in LPS-tolerized macrophages.

Provider

Erpantech Laboratory

download

MSDS-AB-07-2188.pdf (180 downloads )